These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 12032404)

  • 1. Distal deep venous thrombosis in a hemophilia A patient with inhibitor and severe infectious disease, 18 days after recombinant activated factor VII transfusion.
    Van der Planken MG; Schroyens W; Vertessen F; Michiels JJ; Berneman ZN
    Blood Coagul Fibrinolysis; 2002 Jun; 13(4):367-70. PubMed ID: 12032404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors.
    Abshire T; Kenet G
    J Thromb Haemost; 2004 Jun; 2(6):899-909. PubMed ID: 15140125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high-responding inhibitors.
    Smith OP
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():22-5. PubMed ID: 12214142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The continuous infusion of recombinant activated factor VIIa (rFVIIa) in patients with factor VIII inhibitors activates the coagulation and fibrinolytic systems without clinical complications.
    Baudo F; Redaelli R; Caimi TM; Mostarda G; Somaini G; de Cataldo F
    Thromb Res; 2000 Jul; 99(1):21-4. PubMed ID: 10904100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of recombinant activated factor VII (rFVIIa) during acute bleeding episode and surgery in a patient with acquired hemophilia A with high inhibitor titer.
    Franchini M; Capra F; Capelli C; de Maria E; Lippi G; Gandini G
    Haematologica; 2001 Apr; 86(4):E12. PubMed ID: 11325664
    [No Abstract]   [Full Text] [Related]  

  • 6. Recombinant factor VIIa (Novoseven) and the safety of treatment.
    Roberts HR
    Semin Hematol; 2001 Oct; 38(4 Suppl 12):48-50. PubMed ID: 11735111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute myocardial infarction following administration of recombinant activated factor VII (Novo Seven) in a patient with haemophilia A and inhibitor.
    Peerlinck K; Vermylen J
    Thromb Haemost; 1999 Dec; 82(6):1775-6. PubMed ID: 10613674
    [No Abstract]   [Full Text] [Related]  

  • 8. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
    Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
    Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant factor VIIa: unregulated continuous use in patients with bleeding and coagulopathy does not alter mortality and outcome.
    Ganguly S; Spengel K; Tilzer LL; O'neal B; Simpson SQ
    Clin Lab Haematol; 2006 Oct; 28(5):309-12. PubMed ID: 16999720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitor treatment: state of the art.
    Shapiro A
    Semin Hematol; 2001 Oct; 38(4 Suppl 12):26-34. PubMed ID: 11735107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding.
    Smith MP; Ludlam CA; Collins PW; Hay CR; Wilde JT; Grigeri A; Melsen T; Savidge GF
    Thromb Haemost; 2001 Oct; 86(4):949-53. PubMed ID: 11686351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
    Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL
    Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous infusion of recombinant factor VIIa in hemophilic patients with inhibitors: safety, monitoring, and cost effectiveness.
    Schulman S;
    Semin Thromb Hemost; 2000; 26(4):421-4. PubMed ID: 11092218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patients.
    Ng HJ; Lee LH
    Vasc Health Risk Manag; 2006; 2(4):433-40. PubMed ID: 17323597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity.
    Aledort LM
    J Thromb Haemost; 2004 Oct; 2(10):1700-8. PubMed ID: 15456478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transfusion medicine service policies for recombinant factor VIIa administration.
    Goodnough LT; Lublin DM; Zhang L; Despotis G; Eby C
    Transfusion; 2004 Sep; 44(9):1325-31. PubMed ID: 15318856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
    Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
    Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful management of massive intraperitoneal bleeding in a hemophilia A patient with inhibitor by surgical debridement of the incomplete hematoma and administration of recombinant factor VIII and activated factor VII.
    Koyama T; Nagao T; Tsunozaki H; Arai M; Miura O
    Pathophysiol Haemost Thromb; 2006; 35(5):405-7. PubMed ID: 17230044
    [No Abstract]   [Full Text] [Related]  

  • 19. Middle cerebral arterial thrombosis in a patient with hypofibrinogenemia, 5 days after rFVIIa and FFP infusion.
    Patiroglu T; Karakukcu M
    Clin Appl Thromb Hemost; 2006 Jan; 12(1):111-3. PubMed ID: 16444445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The concept of recombinant factor VIIa megadose for treating bleeding episodes in high-titer inhibitor patients with hemophilia: toward an expanding indication?
    Negrier C
    J Thromb Haemost; 2003 Mar; 1(3):423-4. PubMed ID: 12871444
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.